Related references
Note: Only part of the references are listed.US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey
Mark G. Lebwohl et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2016)
Psychological Interventions in the Treatment of Chronic Itch
Christina Schut et al.
ACTA DERMATO-VENEREOLOGICA (2016)
Current and Emerging Therapies for Itch Management in Psoriasis
Carolyn Stull et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2016)
Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis
A. B. Kimball et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials
Bruce Strober et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2016)
Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials
Alexandra B. Kimball et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Clinical meaningfulness of complete skin clearance in psoriasis
Bruce Strober et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Christopher E. M. Griffiths et al.
LANCET (2015)
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
M. Lebwohl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pruritus and quality of life in moderate-to-severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study
U. Mrowietz et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
Participation of interleukin 17A in neuroimmune interactions
Derek M. Moynes et al.
BRAIN BEHAVIOR AND IMMUNITY (2014)
Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial
B. Zhu et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
Reliability and validity of the psoriasis symptom inventory in patients with moderate-to-severe psoriasis
Dennis A. Revicki et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2014)
Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity
David Roblin et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity
Donald M. Bushnell et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2013)
Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity
Mona L. Martin et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2013)
Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin
C. Johansen et al.
BRITISH JOURNAL OF DERMATOLOGY (2009)
The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups
Denise Globe et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2009)
Mediators of pruritus in psoriasis
Adam Reich et al.
MEDIATORS OF INFLAMMATION (2007)
Share Paper
